Overview

Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Status:
NOT_YET_RECRUITING
Trial end date:
2030-10-24
Target enrollment:
Participant gender:
Summary
Tislelizumab combined with chemotherapy and all trans retinoic acid for locally advanced or metastatic esophageal squamous cell carcinoma: a prospective, double-blind, multicenter, randomized controlled phase II trial
Phase:
PHASE2
Details
Lead Sponsor:
Fudan University